WO2012075361A3 - In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents - Google Patents

In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents Download PDF

Info

Publication number
WO2012075361A3
WO2012075361A3 PCT/US2011/063006 US2011063006W WO2012075361A3 WO 2012075361 A3 WO2012075361 A3 WO 2012075361A3 US 2011063006 W US2011063006 W US 2011063006W WO 2012075361 A3 WO2012075361 A3 WO 2012075361A3
Authority
WO
WIPO (PCT)
Prior art keywords
click chemistry
therapeutic
vivo
diagnostic
diagnostic agents
Prior art date
Application number
PCT/US2011/063006
Other languages
French (fr)
Other versions
WO2012075361A2 (en
Inventor
William J. Mcbride
Christopher A. D'souza
David M. Goldenberg
Original Assignee
Immunomedics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/958,889 external-priority patent/US8202509B2/en
Application filed by Immunomedics, Inc. filed Critical Immunomedics, Inc.
Priority to CA2814962A priority Critical patent/CA2814962A1/en
Priority to AU2011336396A priority patent/AU2011336396B2/en
Priority to CN2011800548970A priority patent/CN103221072A/en
Priority to EP11846041.9A priority patent/EP2646055A4/en
Publication of WO2012075361A2 publication Critical patent/WO2012075361A2/en
Publication of WO2012075361A3 publication Critical patent/WO2012075361A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.
PCT/US2011/063006 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents WO2012075361A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2814962A CA2814962A1 (en) 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
AU2011336396A AU2011336396B2 (en) 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CN2011800548970A CN103221072A (en) 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
EP11846041.9A EP2646055A4 (en) 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41908210P 2010-12-02 2010-12-02
US61/419,082 2010-12-02
US12/958,889 US8202509B2 (en) 2007-01-11 2010-12-02 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US12/958,889 2010-12-02

Publications (2)

Publication Number Publication Date
WO2012075361A2 WO2012075361A2 (en) 2012-06-07
WO2012075361A3 true WO2012075361A3 (en) 2012-07-26

Family

ID=46172588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063006 WO2012075361A2 (en) 2010-12-02 2011-12-02 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents

Country Status (5)

Country Link
EP (1) EP2646055A4 (en)
CN (1) CN103221072A (en)
AU (1) AU2011336396B2 (en)
CA (1) CA2814962A1 (en)
WO (1) WO2012075361A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101416290B1 (en) * 2012-03-20 2014-07-09 한국과학기술연구원 Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry
WO2014138186A1 (en) * 2013-03-05 2014-09-12 The Johns Hopkins University Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics
ES2759503T3 (en) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
CN103951668A (en) * 2014-04-25 2014-07-30 广州军区广州总医院 Positron isotope label of folic acid ramification and application thereof
CN104529898B (en) * 2015-01-15 2016-07-27 成都丽凯手性技术有限公司 Azepine dibenzo cyclooctyne compounds and preparation method thereof
CN108289932A (en) * 2015-05-22 2018-07-17 D·D·格恩金 Extracellular dna is as neurodegenerative therapy target
WO2017007807A1 (en) * 2015-07-07 2017-01-12 Immunomedics, Inc. IMPROVED METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
KR20220101204A (en) 2016-03-02 2022-07-19 에자이 알앤드디 매니지먼트 가부시키가이샤 Eribulin-based antibody-drug conjugates and methods of use
CN111491670A (en) * 2017-12-18 2020-08-04 詹森生物科技公司 Radiolabelling of polypeptides
CN109675052B (en) * 2019-01-29 2022-02-15 中国药科大学 Efficient targeting conjugate triggered by biological click, and multi-component composition, preparation method and application thereof
CN112457401B (en) * 2020-10-21 2023-02-24 上海交通大学医学院附属仁济医院 Molecular imaging probe for diagnosing multiple myeloma
CN113372413B (en) * 2021-05-17 2022-09-27 复旦大学附属中山医院 PET (polyethylene terephthalate) imaging agent targeting CD11b receptor, labeled precursor thereof, preparation method, composition and application thereof
CN113476619B (en) * 2021-07-08 2022-11-29 上海交通大学医学院附属仁济医院 A kind of 18 F-labeled nano antibody probe and preparation method and application thereof
CN115282299B (en) * 2022-07-20 2024-01-12 北京大学深圳研究生院 TGF beta tracer, antibody probe preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246130A1 (en) * 2007-01-11 2009-10-01 Immunomedics, Inc. Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules
US20100104589A1 (en) * 2002-12-13 2010-04-29 Immunomedics, Inc. Immunoconjugates with an Intracellularly-Cleavable Linkage
US20100234450A1 (en) * 2008-08-09 2010-09-16 Schultz Michael K Molecular targeting agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
EP2331134A4 (en) * 2008-08-08 2014-10-15 Immunomedics Inc Anti-pancreatic cancer antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104589A1 (en) * 2002-12-13 2010-04-29 Immunomedics, Inc. Immunoconjugates with an Intracellularly-Cleavable Linkage
US20090246130A1 (en) * 2007-01-11 2009-10-01 Immunomedics, Inc. Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules
US20100234450A1 (en) * 2008-08-09 2010-09-16 Schultz Michael K Molecular targeting agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: "Copper-free click chemistry in living animais.", PNAS., vol. 107, 2010, pages 1821 - 1826, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836626/?tool=pubmed> [retrieved on 20120521] *
KIICK ET AL.: "Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation.", PNAS., vol. 99, 2002, pages 19 - 24, XP002904363, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmclarticles/PMC117506/?tool=pubmed> [retrieved on 20120521], DOI: doi:10.1073/pnas.012583299 *
See also references of EP2646055A4 *

Also Published As

Publication number Publication date
EP2646055A2 (en) 2013-10-09
AU2011336396B2 (en) 2016-02-04
WO2012075361A2 (en) 2012-06-07
CA2814962A1 (en) 2012-06-07
EP2646055A4 (en) 2015-04-08
CN103221072A (en) 2013-07-24
AU2011336396A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
WO2012075361A3 (en) In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
Shukla et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb
Pi et al. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery
Li et al. A new interleukin-13 amino-coated gadolinium metallofullerene nanoparticle for targeted MRI detection of glioblastoma tumor cells
Wang et al. Design and synthesis of [111In] DTPA− folate for use as a tumor-targeted radiopharmaceutical
Verma et al. The cryptophycins as potent payloads for antibody drug conjugates
Deshmukh et al. A series of α-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity
CN104334178B (en) Targeting self assembly of the functionalized carbon nano-tube in tumour
NZ589086A (en) Human serum albumin (HSA) linkers and conjugates thereof
WO2011002852A3 (en) Pro-drug complexes and related methods of use
IN2012DN03177A (en)
WO2007040469A3 (en) Chloroquine coupled compositions and methods for their synthesis
WO2016046793A3 (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells
WO2008137758A3 (en) Amino acid lipids and uses thereof
Yang et al. Galactosylated poly (2-(2-aminoethyoxy) ethoxy) phosphazene/DNA complex nanoparticles: in vitro and in vivo evaluation for gene delivery
WO2010059253A3 (en) Methods and compositions for localized agent delivery
WO2011028334A3 (en) Synthesis and isolation of dendrimer systems
MX2010003718A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates.
EA032867B9 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
UA91512C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
NZ606480A (en) Albumin binding peptide-mediated disease targeting
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2010046900A3 (en) Rgd-containing peptidomimetics and uses thereof
EP3450459A3 (en) Anti-cdh3 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846041

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2814962

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011336396

Country of ref document: AU

Date of ref document: 20111202

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011846041

Country of ref document: EP